About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ESPR - Esperion Therapeutic...| Previous Close | $27.68 | Open | $27.89 |
| Volume | 704.7K | Market Cap | 771.63M |
| Yield | Last Dividend |
| The Week Ahead In Biotech: J&J Vaccine A... | 02/20/21 |
| Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pa... | |
| Esperion to Report Fourth Quarter and Fu... | 02/09/21 |
| ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financia... | |
| Why Novartis, BioVie, Esperion And VBI A... | 01/15/21 |
| Esperion Therapeutics (NASDAQ: ESPR ) shares are trading lower ??? Full story available on Benzinga.com | |
| Why BioLine, Esperion And More Are Movin... | 12/16/20 |
| Esperion Therapeutics (NASDAQ: ESPR ) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholest... | |
| The Daily Biotech Pulse: Alzheimer's Con... | 11/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-... | |
| Esperion Therapeutics, Inc. (ESPR) CEO T... | 11/02/20 |
| Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2020 Earnings Conference Call November 02, 2020 4:30 PM ET Company Participants Ben Church - Investor Rel... | |
| Esperion Therapeutics (NASDAQ:ESPR) Stoc... | 10/19/20 |
| BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a sell rating to a hold rating in a research report sent to investors on Saturd... | |
| Why Is Esperion Therapeutics (ESPR) Down... | 06/05/20 |
| Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| All You Need to Know About Esperion Ther... | 06/04/20 |
| Esperion Therapeutics (ESPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 ... | |
| The Daily Biotech Pulse: FDA Nod For Roc... | 06/02/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adap... | |
| IN BRIEF: Judge certifies Esperion inves... | 06/01/20 |
| A federal judge has certified a class of Esperion Therapeutics Inc shareholders in a lawsuit alleging the company falsely stated that the U.S. Food an... | |
| Esperion Therapeutics' Festive Q1 2020 E... | 05/13/20 |
| Esperion Therapeutics (ESPR) recently caught my eye because of a newly announced 256% upside target from Needham. This article reflects my evaluation ... | |
| Esperion's Cholesterol Drugs Receive App... | 04/07/20 |
| Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe. | |
| The Week Ahead In Biotech: COVID-19 Stoc... | 02/29/20 |
| Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likel... | |
| Esperion (ESPR) Q4 Earnings and Revenues... | 02/28/20 |
| Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month. | |
| A tiny biotech's huge bet on a heart pil... | 02/21/20 |
| Esperion Therapeutics just got its first heart drug approved in the US, and the CEO told Business Insider the company is pricing the cholesterol-lower... | |
| The Daily Biotech Pulse: Epizyme's Tazem... | 02/14/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs F... | |
| Stock Alert: Esperion Therapeutics (ESPR... | 02/13/20 |
| Esperion Therapeutics Inc. (ESPR) has been hitting new highs and is already up nearly 24 percent so far this year.. | |
| The Daily Biotech Pulse: Deciphera Cance... | 02/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) ... | |
| The Daily Biotech Pulse: J&J Intensifies... | 02/12/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) ... | |
| The Daily Biotech Pulse: LogicBio Slappe... | 02/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) ... | |
| The Daily Biotech Pulse: Xeris Jumps On ... | 01/07/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs o... | |
| The Daily Biotech Pulse: Acorda Surges A... | 01/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) A... | |
| Esperion (ESPR) Almost Doubled In 2019, ... | 01/02/20 |
| Shares of Esperion Therapeutics Inc. (ESPR), which closed at a new 52-week high of $61.34, have gained more than 60% over the last 3 months.. | |
| The Daily Biotech Pulse: Qiagen Opts To ... | 12/26/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs D... | |
| Esperion Therapeutics (ESPR) Up 25.1% Si... | 12/06/19 |
| Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Esperion's Promising Drugs Under Review,... | 11/28/19 |
| Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, abse... | |
| AbbVie, Nokia, Lululemon Athletica: 'Mad... | 11/21/19 |
| Jim Cramer takes a look at AbbVie, Nokia, Lululemon Athletica, Plug Power, Esperion Therapeutics, Alarm.com, First Horizon National and more. | |
| Esperion Therapeutics (ESPR) Catches Eye... | 11/19/19 |
| Esperion Therapeutics (ESPR) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes. | |
| Esperion Therapeutics (ESPR) Down 10.8% ... | 09/07/19 |
| Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| rating | 02/24/21 |
| Needham maintains Strong Buy rating and lowers Price Target from $150.00 to $134.00 | |
| Hold rating | 02/12/21 |
| Jefferies downgrades from Buy to Hold rating and lowers Price Target from $40.00 to $30.00 | |
| Sell rating | 02/09/21 |
| Goldman Sachs downgrades from Neutral to Sell rating and announces Price Target of $24.00 | |
| Hold rating | 01/15/21 |
| B of A Securities downgrades from Buy to Neutral rating and lowers Price Target from $52.00 to $35.00 | |
| Date | 2021-02-23 (AMC) | Est. (EPS/Rev.) | ($3.76)/ 12.52M |
| Actual (EPS/Rev.) | $-3.89/ $9.64 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swingtrades | R. belegger | 83.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| It's only money | Gavin wells | 58.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
